文献速递肝病消化道肿瘤与早癌

荟萃分析:免疫相关不良事件与肝细胞癌免疫检查点抑制剂疗效改善相关

Meta-Analysis: Immune-Related Adverse Events Are Associated With Improved Effectiveness of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2025-10-21

该荟萃分析纳入24项回顾性研究共4798例肝细胞癌患者,评估免疫相关不良事件(irAEs)与免疫检查点抑制剂(ICIs)疗效的关系。结果显示irAEs发生与更优的客观缓解率、疾病控制率、无进展生存期和总生存期相关,皮肤和内分泌irAEs及低级别irAEs与生存改善相关,而肺、胃肠和肝胆irAEs无此关联;用于管理irAEs的皮质类固醇使用未损害生存。

要点

  • irAEs发生与肝细胞癌ICIs治疗更优的ORR、DCR、PFS和OS相关。
  • 皮肤和内分泌irAEs及低级别irAEs与生存改善相关,高级别事件无此关联。
  • 用于管理irAEs的皮质类固醇使用未损害生存获益。

核心结论

  • irAEs特别是皮肤、内分泌和低级别事件与肝细胞癌ICIs疗效改善相关,早期识别irAEs并使用皮质类固醇管理可保留生存获益。

主要发现

  • irAEs发生与更优ORR相关(OR 2.18,95%CI 1.64-2.89)。
  • irAEs发生与更优DCR相关(OR 3.09,95%CI 1.81-5.27)。
  • irAEs发生与更优PFS相关(HR 0.62,95%CI 0.51-0.75)。
  • irAEs发生与更优OS相关(HR 0.76,95%CI 0.61-0.95)。
  • 皮肤和内分泌irAEs与PFS改善相关(HR分别为0.45和0.50)及OS改善相关(HR分别为0.51和0.59),肺、胃肠和肝胆irAEs未显示此类关联。

关键数值与推荐

  • 低级别irAEs(1-2级)与更好生存相关(PFS HR 0.47;OS HR 0.48),高级别事件无此关联。
  • 用于irAEs管理的皮质类固醇使用未损害生存(PFS HR 0.97;OS HR 0.91)。

临床怎么用

  • 在肝细胞癌ICIs治疗中,发生皮肤、内分泌或低级别irAEs可能提示更好疗效,应早期识别并规范使用皮质类固醇管理,无需因担心疗效受损而回避激素。

局限性

  • 纳入研究均为回顾性研究,需更多大规模前瞻性研究验证 findings。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While immune-related adverse events (irAEs) have been linked to improved outcomes in melanoma and non-small cell lung cancer (NSCLC), their prognostic role in hepatocellular carcinoma (HCC), a malignancy arising in a unique immune microenvironment shaped by chronic inflammation and cirrhosis, remains unexplored. This meta-analysis investigated the relationship between irAEs and the effectiveness of immune checkpoint inhibitors (ICIs) in HCC. METHODS: Following PRISMA guidelines, we systematically reviewed studies from PubMed, Embase and the Cochrane Library (through December 2024) that evaluated the association between irAEs and ICIs' effectiveness in HCC. The primary outcomes were progression-free survival (PFS) and overall survival (OS), and the secondary outcomes were objective response rate (ORR) and disease control rate (DCR). Subgroup analyses assessed irAEs' types, severity and corticosteroid impact. RESULTS: Among 24 retrospective studies (4798 patients), irAEs occurrence correlated with superior ORR (OR, 2.18; 95% CI, 1.64-2.89), DCR (OR, 3.09; 95% CI, 1.81-5.27), PFS (HR, 0.62; 95% CI, 0.51-0.75) and OS (HR, 0.76; 95% CI, 0.61-0.95). Dermatologic and endocrine irAEs were associated with improved survival (PFS: HR, 0.45 and 0.50; OS: HR, 0.51 and 0.59, respectively), while pulmonary, gastrointestinal and hepatobiliary irAEs did not show such relations. Low-grade irAEs (Grades 1 and 2) were linked to better survival (PFS: HR, 0.47; OS: HR, 0.48), unlike high-grade events. Corticosteroid use for irAEs management did not impair survival (PFS: HR, 0.97; OS: HR, 0.91). CONCLUSION: irAEs, particularly dermatologic, endocrine and low-grade events, were associated with improved ICIs' effectiveness in HCC. Early irAEs detection and corticosteroid management preserve survival benefits. However, more large-scale prospective studies are needed to verify our findings.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Liu S, Li Z, Lin J, et al. Meta-Analysis: Immune-Related Adverse Events Are Associated With Improved Effectiveness of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2025. PMID: 41116751. doi:10.1111/apt.70427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。